Core Insights - The World Conference on Lung Cancer (WCLC) has selected 10 lung cancer research abstracts from the company, including 4 oral presentations and 2 poster discussions, covering key clinical scenarios in non-squamous/squamous non-small cell lung cancer (nsNSCLC/sqNSCLC) and extensive small cell lung cancer (ES-SCLC) first-line treatments [1] - The selected studies focus on three core products: PD-L1 ADC HLX43, PD-1 monoclonal antibody Surufatinib (Hansizhuang®), and anti-EGFR monoclonal antibody HLX07, with HLX43 being the first PD-L1 ADC to enter Phase II globally, showing excellent efficacy in gene-negative NSCLC populations [1] - Surufatinib is the first PD-1 monoclonal antibody approved for first-line treatment of SCLC, currently approved in nearly 40 countries and regions worldwide [1] - HLX07 combined with immunotherapy achieved a 100% disease control rate (DCR) and 17.4 months progression-free survival (PFS) in EGFR high-expressing lung squamous carcinoma, demonstrating strong survival benefits [1] Market Reaction - The market reacted positively to the company's global expansion and innovation capabilities, with the stock price reaching approximately 79 HKD [2] - Citigroup's latest report indicated that data updates for HLX43 at WCLC are expected to further validate its potential in NSCLC treatment, raising the company's target price from 35 HKD to 95 HKD while maintaining a "Buy/High Risk" rating [2] - The report suggests that the progress of the company's innovative pipeline will continue to drive valuation reassessment [2]
复宏汉霖(02696)肺癌管线三箭齐发登国际顶会 HLX43数据成最大催化剂 获花旗上调目标价至95港元